1. The change of uNTx/uCr (a marker of bone resorption) was within the equivalence margin in the MW032 group and...

1. The objective response rate was 28% with a complete response of 5.6% and a partial response of 23%. 2....

1. Adding subcutaneous daratumumab to VRd (bortezomib, lenalidomide, and dexamethasone) induction/consolidation, and lenalidomide maintenance therapy improves progression-free survival in eligible...

1. There was no kidney rejection noted in the cemiplimab for kidney transplant recipients. 2. Cemiplimab was found to have...

1. Low dose Olanzapine (2.5 mg) demonstrated similar anti-emetic effect to standard dose olanzapine in patients receiving emetogenic chemotherapy 2....

1. While perceived appetite did not differ between study groups, patients receiving mirtazapine had significantly increased caloric consumption compared with...

1. The median progression-free survival was improved with the pooled subtyping-based therapy group compared to the control group (11.3 months...

1. In patients with low tumor burden follicular lymphoma (LTBFL): Rituximab maintenance therapy does not improve overall survival in comparison...

1. The median overall survival and event-free survival were not statistically different in the pembrolizumab group as compared to the...

1. Progression-free survival in NSCLC was found to be significant with HR 0.41 compared to breast cancer which was non-significant...